Ma Jingwen, Li Hongmei, Han Shuxia
Altern Ther Health Med. 2024 Jun 14.
Vaginal Intraepithelial Neoplasia (VaIN) is a prevalent condition that can progress to invasive carcinoma if left untreated. Despite its significance, effective treatments for VaIN remain limited.
This study aimed to analyze the efficacy of Paiteling in treating VaIN among patients who have undergone total hysterectomy due to high cervical lesions or invasive cervical cancer.
This study employed a retrospective design.
The study was conducted at Ningxia General Hospital of Medical University from January 2019 to January 2023.
A total of 67 cases diagnosed with VaIN were included in the study. Inclusion criteria comprised patients who had undergone total hysterectomy for high cervical lesions or invasive cervical cancer and had confirmed VaIN diagnosis through abnormal ThinPrep Cytology Test (TCT) and/or High-risk Human Papillomavirus (HR-HPV) results with colposcopy biopsy.
Patients were treated with Chinese patent medicines Paiteling and patulin according to their specific VaIN classification: VaIN1, VaIN2, and VaIN3.
The primary outcome measures included complete negative conversion rates for VaIN1, VaIN2, and VaIN3, as well as overall effective rate and complete negative rate across all VaIN cases. Statistical analysis was performed using IBM SPSS 24.0, with significance set at P < .05.
Patients with VaIN1, VaIN2, and VaIN3 were treated with Chinese patent medicines Paiteling, and patulin, respectively. Complete negative conversion rates were 100% for VaIN1, 72.73% for VaIN2, and 75.67% for VaIN3, resulting in an overall effective rate of 88.89% and a complete negative rate of 72.22% across all VaIN cases.
This study underscores the efficacy of Chinese patent medicine Paiteling in managing post-total hysterectomy VaIN. It presents a conservative treatment option for vaginal stump diseases, addressing a crucial gap in therapeutic strategies. The findings advocate for further exploration of Paiteling's potential in VaIN management.
阴道上皮内瘤变（VaIN）是一种常见病症，若不治疗可能进展为浸润性癌。尽管其具有重要性，但针对VaIN的有效治疗方法仍然有限。
本研究旨在分析派特灵对因宫颈高级别病变或浸润性宫颈癌而行全子宫切除术患者的VaIN治疗效果。
本研究采用回顾性设计。
研究于2019年1月至2023年1月在宁夏医科大学总医院进行。
本研究共纳入67例诊断为VaIN的患者。纳入标准包括因宫颈高级别病变或浸润性宫颈癌而行全子宫切除术，且经薄层液基细胞学检测（TCT）异常和/或高危型人乳头瘤病毒（HR-HPV）结果及阴道镜活检确诊为VaIN的患者。
根据患者具体的VaIN分级（VaIN1、VaIN2和VaIN3），使用中成药派特灵和制霉菌素进行治疗。
主要观察指标包括VaIN1、VaIN2和VaIN3的完全转阴率，以及所有VaIN病例的总有效率和完全转阴率。使用IBM SPSS 24.0进行统计分析，显著性水平设定为P < .05。
VaIN1、VaIN2和VaIN3患者分别接受了中成药派特灵和制霉菌素治疗。VaIN1的完全转阴率为100%，VaIN2为72.73%，VaIN3为75.67%，所有VaIN病例的总有效率为88.89%，完全转阴率为72.22%。
本研究强调了中成药派特灵在全子宫切除术后VaIN治疗中的疗效。它为阴道残端疾病提供了一种保守治疗选择，填补了治疗策略中的关键空白。研究结果提倡进一步探索派特灵在VaIN治疗中的潜力。
